Information Provided By: 
Fly News Breaks for May 9, 2019
PTI
May 9, 2019 | 18:04 EDT
Piper Jaffray analyst Edward Tenthoff lowered his price target on Proteostasis to $5 after its Q1 results that disclosed the company's $105M cash position and also to reflect its recently reported disappointing Phase 1 TripleRx data in homozygous F508del CF patients. The analyst maintains his Overweight rating on the stock but also lowers his estimate for Proteostasis' proprietary TripleRx regimen in the U.S. at $128M vs. $293M prior view.
News For PTI From the Last 2 Days
There are no results for your query PTI
